TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from NervGen Pharma ( (TSE:NGEN) ) is now available.
NervGen Pharma has announced a US$10 million non-brokered private placement to support its anticipated Nasdaq listing and advance the development of NVG-291. This financing involves participation from both new and existing investors, including SCI Ventures, and reflects confidence in NervGen’s clinical progress. The proceeds will be used to further NVG-291’s clinical development and for general corporate purposes, marking a pivotal chapter in the company’s evolution into a late-stage biotech firm.
The most recent analyst rating on (TSE:NGEN) stock is a Buy with a C$5.00 price target. To see the full list of analyst forecasts on NervGen Pharma stock, see the TSE:NGEN Stock Forecast page.
Spark’s Take on TSE:NGEN Stock
According to Spark, TipRanks’ AI Analyst, TSE:NGEN is a Neutral.
NervGen Pharma presents a high-risk, high-reward profile typical of early-stage biotech firms. Financial performance is weak due to ongoing R&D costs with no revenue, but technical indicators show positive momentum. Corporate events highlight potential upside from clinical advancements. However, the lack of earnings and reliance on financing remain significant concerns.
To see Spark’s full report on TSE:NGEN stock, click here.
More about NervGen Pharma
NervGen Pharma Corp. is a clinical-stage biopharmaceutical company focused on developing neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic disorders. The company is working on NVG-291, a potential regenerative drug for chronic spinal cord injury, aiming to transform the lives of individuals affected by such conditions.
Average Trading Volume: 87,418
Technical Sentiment Signal: Buy
Current Market Cap: C$245M
See more data about NGEN stock on TipRanks’ Stock Analysis page.